# IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)

> **NCT06647862** · PHASE3 · RECRUITING · sponsor: **ImmuneOnco Biopharmaceuticals (Shanghai) Inc.** · enrollment: 170 (estimated)

## Conditions studied

- Chronic Myelomonocytic Leukemia

## Interventions

- **DRUG:** IMM01
- **DRUG:** Azacitidine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06647862
- **Lead sponsor:** ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-11
- **Primary completion:** 2026-04-24
- **Final completion:** 2029-10-24
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06647862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06647862, "IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06647862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*